Navigation Links
Metformin Outperforms Common Class of Diabetes Drugs in Study
Date:6/24/2012

SUNDAY, June 24 (HealthDay News) -- Three widely used diabetes drugs are associated with a greater risk of death when compared to a popular drug from a different class, metformin, according to a new study.

Researchers analyzed data from nearly 24,000 patients with type 2 diabetes, average age 62, who were treated with one of three drugs called sulfonylureas (glipizide, glyburide, and glimepiride) or with another type of drug called metformin.

Sulfonylureas help decrease blood sugar levels by stimulating the pancreas to produce insulin. Metformin also helps reduce blood sugar levels.

Overall, all three sulfonylureas were associated with a more than 50 percent greater risk of death compared to metformin, according to the study, which was funded by drug company Astra Zeneca.

The researchers also found that, among diabetes patients with heart disease, glipizide was associated with a 41 percent greater risk of death and glyburide was associated with a 38 percent greater risk of death, compared with glimepiride and metformin.

According to one expert not connected to the study, the new data could provide some guidance for patients.

"Patients taking sulfonylureas should be made aware of this increased risk of death and other oral options for glycemic [blood sugar] control should be discussed," said Dr. Spyros Mezitis, an endocrinologist at Lenox Hill Hospital in New York City.

The study was to be presented Sunday at The Endocrine Society's annual meeting in Houston.

"We have clearly demonstrated that metformin is associated with a substantial reduction in mortality risk, and, thus, should be the preferred first-line agent, if one has a choice between metformin and a sulfonylurea," said study author Dr. Kevin M. Pantalone, an endocrinologist at Summa Western Reserve Hospital in Cuyahoga Falls, Ohio.

He conducted the study with a team of researchers from Cleveland Clinic.

Another expert said the study may have "enormous clinical implications."

Dr. Minisha Sood, also an endocrinologist at Lenox Hill, said that sulfonylureas may fare worse than metformin because the former might "interfere" with cardiovascular processes that strengthen and protect heart tissue so it becomes more resilient should a cardiac event occur.

"What's interesting about this study is that all three sulfonylureas examined led to increased mortality rates vs. metformin in the entire cohort study, which included patients without coronary artery disease," Sood added. "Does this mean that we shouldn't be prescribing sulfonylureas at all? I think prospective trials are needed to answer that question, so the jury is still out."

Nearly 26 million people in the United States have diabetes, according to the U.S. Centers for Disease Control and Prevention. Many of these patients also have other health problems, including heart disease.

Findings presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about diabetes medicines.

-- Robert Preidt

SOURCES: Spyros Mezitis, M.D., and Minisha Sood, M.D., endocrinologists, Lenox Hill Hospital, New York City; The Endocrine Society, news release, June 24, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
2. Texting in College Classrooms Common, Distracting
3. Recovery from propofol anesthesia may be sped by use of common stimulant
4. Long-term neuropsychological impairment is common in acute lung injury survivors
5. Overuse Injuries Common Among Female College Athletes
6. Common Blood Pressure Drug Safe for Heart Failure: Study
7. Test links strains of common parasite to severe illness in US newborns
8. Common Plastics Chemical Might Boost Diabetes Risk
9. Off-Label Drug Use Appears Common
10. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
11. Slow-growing babies more likely in normal-weight women; Less common in obese pregnancies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Metformin Outperforms Common Class of Diabetes Drugs in Study
(Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, the ... – London is home to Ontario’s leading day spa and one of Canada’s few ... began with a unique concept to combine spa services with hair and beauty ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... WaterField Designs, ... digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit , the ideal ... canvas or ballistic nylon, the Duo is smartly designed for Dad’s grooming ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Spectrum Aquatics has ... new lift has been designed and built with the user in mind. , “Over ... consultants have informed us that an ADA 400 lbs lift is a necessary requirement ...
(Date:5/31/2016)... CA (PRWEB) , ... May 31, 2016 , ... Interest ... a primary screening tool and as an orthogonal tool for RNAi hit validation. A ... functional and specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed ...
(Date:5/31/2016)... ... May 31, 2016 , ... TeaZa® Energy, LLC announces ... on World No Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be ... this summer. , The new flavor is best described as a juicy, taste ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 Since its commercial introduction ... essential life science tool for conducting genetic studies in ... reveals in its new report that the industry sits ... powered by a range of new applications in the ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
(Date:5/25/2016)... , May 25, 2016 As ... Expo earlier this month, the numbers and momentum of ... to climb into the billions, more research and development ... 4th Edition State of Legal Marijuana Markets Report  from ... data-analysis firm, much of the increase in sector is ...
Breaking Medicine Technology: